Flucloxacillin and paracetamol induced pyroglutamic acidosis
Authors:
Open Access
- 8 January 2021
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 14 (1) , e237536
Abstract
A 75-year-old woman was admitted to a regional hospital with an acute kidney injury (AKI) and nausea on a background of recent treatment for Staphylococcus aureus bacteraemia secondary to pneumonia. The treatment thereof resulted in a high anion gap metabolic acidosis (HAGMA). The pneumonia was initially treated with intravenous piperacillin and tazobactam and the patient transferred to a tertiary hospital. There, the diagnosis of S. aureus bacteraemia secondary to a pulmonary source was confirmed and treatment was changed to intravenous flucloxacillin and the patient was discharged to hospital in the home (HITH is a service that allows short-term healthcare at home to be provided to people who would otherwise need to be in hospital) to complete the antibiotic course. Five weeks after commencing flucloxacillin, the patient was referred back to hospital with nausea and worsening kidney function with an associated significant HAGMA. The patient has a background of chronic kidney disease and chronic back pain for which she was taking long-term paracetamol. The HAGMA was determined to be due to a pyroglutamic acidosis (PGA), deemed secondary to the combined use of paracetamol and flucloxacillin. This was subsequently confirmed with a plasma pyroglutamic acid concentration level of 7467 µmol/L (reference range 20–50 µmol/L) and a urinary level of 1700 mmol/mol creatinine (<110 mmol/mol creatinine). To our knowledge, this is the highest plasma and urinary levels published to date. Furthermore, considering the common use of paracetamol and penicillins, it is important to recognise HAGMA as a potential complication of co-administration of paracetamol and iso-oxylopenicillin. The HAGMA resolved after cessation of flucloxacillin despite the continuation of paracetamol and without administration of N-acetylcysteine. PGA-related HAGMA appears to be a unique potential side effect of iso-oxylopenicillin rather than other beta-lactams.Keywords
This publication has 27 references indexed in Scilit:
- Acetaminophen Toxicity and 5-Oxoproline (Pyroglutamic Acid)Clinical Journal of the American Society of Nephrology, 2014
- Severe Anion Gap Metabolic Acidosis From Acetaminophen Use Secondary to 5-Oxoproline (Pyroglutamic Acid) AccumulationThe American Journal of the Medical Sciences, 2012
- An unusual case of severe high anion gap metabolic acidosisClinical Kidney Journal, 2011
- Mind the gap! An unusual metabolic acidosisThe Lancet, 2011
- Glutathione Synthesis Is Diminished in Patients With Uncontrolled Diabetes and Restored by Dietary Supplementation With Cysteine and GlycineDiabetes Care, 2010
- Consequences and therapy of the metabolic acidosis of chronic kidney diseasePediatric Nephrology, 2010
- GOLD MARK: an anion gap mnemonic for the 21st centuryThe Lancet, 2008
- 5-Oxoprolinuria in patients with and without defects in the -glutamyl cycleEuropean Journal of Pediatrics, 1999
- Atypical pyroglutamic aciduria: possible role of paracetamolJournal of Inherited Metabolic Disease, 1990
- PYROGLUTAMICACIDURIA FROM VIGABATRINThe Lancet, 1989